S.D. MAYANSKAYA¹, A.A. GILMANOV², G.I. ALIAKBEROVA², A.F. USMANOVA¹, M.M. MANGUSHEVA¹, E.O. TIMOFEEVA¹, D.A. AKHMADIEVA¹

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital, Kazan

 Contact details:

Mayanskaya S.D. — MD, Professor of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-905-316-99-66, e-mail: Smayanskaya@mail.ru

 The issues of recurrent course of cardiovascular diseases are of great importance today. Currently, the causes of stent restenosis, recurrent cardiovascular accidents, and various complications of coronary heart disease, including extracardiac ones, are receiving increasing attention. The article presents a clinical case of a patient with an extreme cardiovascular risk of chronic coronary heart disease, who repeatedly underwent inpatient treatment with acute coronary syndrome (ACS). At the same time, the patient received all the necessary basic therapy — dual antiplatelet therapy and high doses of statins. When searching for causes, including extracardiac ones, the role of polycythemia vera (PV) in the development of these pathological conditions was determined. With this example, we would like to emphasize the need for careful identification of non-cardiac concomitant diseases in patients with recurrent cardiovascular complications (CVC) and a multidisciplinary approach to such patients.

Key words: acute coronary syndrome, extremely high cardiovascular risk, stent restenosis, polycythemia vera, JAK2 gene mutation.

REFERENCES

1. Cergienko I.V. Russian clinical guidelines for lipid metabolism disorders 2024. What’s new? RMZh, 2023, no. 4, pp. 12–16 (in Russ.).
2. Melikyan A.L., Kovrigina A.M., Subortseva I.N. et al. National clinical guidelines for the diagnosis and treatment of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2020). Klinicheskaya onkogematologiya Fundamental’nye issledovaniya i klinicheskaya praktika, 2021, no. 14 (2), pp. 262–298 (in Russ.).
3. Kozlova L., Kuchma G., Sokolova N. et al. Thrombosis of coronary and cerebral vessels at the onset of polycythemia vera (own observation). Vrach, 2019, no. 30 (3), pp. 38–43 (in Russ.).
4. Tremblay D., Yacoub A., Hoffman R. Overview of myeloproliferative neoplasms. Hematol. Oncol. Clin. N Am, 2021, vol. 35, pp. 159–176.
5. Griesshammer M., Kiladjian J.-J., Besses C. Thromboembolic events in polycythemia vera. Ann. Hematol, 2019, vol. 98 (5), pp. 1071–1082.
6. Marchioli R. et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol, 2005, vol. 23, pp. 2224–2232.